论文部分内容阅读
外套细胞淋巴瘤(MCL)作为霍奇金淋巴瘤的一种,其特征为化疗低反应性及化疗后的无进展生存期(PFS)短。大剂量化疗和自体干细胞移植同样不能延长其无病生存。本研究试图用利妥昔联合沙利度胺通过淋巴瘤细胞和微环境两方面起到抗瘤作用。方法所有进入研究的患者均已经接受CHOP(14
Mantle cell lymphoma (MCL), a form of Hodgkin’s lymphoma, is characterized by low response to chemotherapy and poor progression-free survival (PFS) after chemotherapy. High-dose chemotherapy and autologous stem cell transplantation also failed to prolong their disease-free survival. This study attempted to use rituximab in combination with thalidomide to lyse tumor cells and microenvironment both anti-tumor effect. Methods All patients enrolled in the study had already received CHOP (14